Inception Sciences

Welcome


Inception Sciences is a drug discovery engine co-founded with Versant Ventures in 2011, with research sites in the US and Canada. Inception Sciences consists of a seasoned team of drug discoverers with a track record of inventing drugs that have successfully entered the clinic and market. In collaboration with pioneering academic researchers, Inception Sciences has created multiple new start-up companies for translating breakthrough scientific insights into novel therapies.

Drug discovery operations are built around an experienced team of researchers led by Peppi Prasit. Previous accomplishments of Inception team members led to multiple marketed and clinical-stage drugs in diverse disease areas including arthritis, neurology, oncology, fibrosis, osteoporosis, arthritis and respiratory disorders. Prior to Inception, team members comprised Amira Pharmaceuticals, a company backed by Versant and successfully acquired by Bristol Myers Squibb in 2011. Amira discovered five drug candidates entering clinical trials within five years and provided partners a significant “first mover advantage.” Prior to Amira, Peppi and other Inception team members played key roles with Vioxx, Arcoxia, Singulair, odanacatib and other successful programs at Merck.

 


Inception Sciences In the News

June 25, 2014: Versant’s Inception plants its booming biotech startup model in Montreal.
See fiercebiotech.com for more.

June 24, 2014: Montreal - Versant Ventures Expands Canadian Operations with Launch of Inception Sciences in Montreal - Drug Discovery Engine to Create New Companies.
Versant Ventures, a global life sciences venture capital firm, continues its Canadian growth strategy with the launch of biopharmaceutical incubator Inception Sciences in Montreal. Versant, with Inception Sciences, will be working to launch new companies that can accelerate the commercialization of scientific research in the province of Quebec. Press Release: PDF

June 24, 2014: Inception Sciences Appoints Clare Ozawa as Chief Operating Officer
San Diego, Calif. and Vancouver, Canada–Inception Sciences, a drug discovery incubator that launches new companies in collaboration with academia and pharmaceutical companies, today announced that Clare Ozawa, Ph.D. was named Chief Operating Officer.
Clare Ozawa joined Inception Sciences in January 2011 as founding Chief Business Officer. In her new role as COO, Clare will have overall responsibility for Inception’s global operations, including strategic business development, and oversight of Inception’s launch of a new site in Montreal, Canada. Press Release: PDF

June 23, 2014: Tapping UCSF Invention, Roche and Versant Dive Into Myelin Repair
See Xconomy.com.

June 23, 2014: Roche announces partnership to discover novel disease-modifying therapies for multiple sclerosis.
Roche announced today that it has entered into an exclusive partnership with Inception Sciences, Inc., and Versant Ventures to create Inception 5, a new company dedicated to the research and development of novel small molecule remyelinating therapies for patients with multiple sclerosis. Press Release:

Nov. 18, 2013: Bayer HealthCare, Inception Sciences and Versant Ventures Join Forces to Develop Innovative Therapeutics for Retinal Eye Diseases.
Bayer HealthCare, Inception Sciences, Inc. and Versant Ventures will jointly conduct early research in the area of ophthalmology, in a newly created company called “Inception 4”. The goal of this new alliance is to develop treatment options, focused on a novel target and pathway, for patients with eye diseases, such as wet age-related macular degeneration and geographic atrophy.

Click here for more: Inception Sciences in the News

 

Career Opportunities

Associate Chemist Medicinal Chemistry


Contact Us

Inception Sciences, Inc
5871 Oberlin Drive, Suite 100
San Diego, CA 92121

Phone: 858 224.7700
Fax: 858 558.5732

Inquiries
Cathy Stuhler
CStuhler@inceptionsci.com
Phone: 858 224.7701

 

Click map for directions:
MAP

 

© Copyright Inception Sciences, Inc. 2014. All rights reserved